Prolonged infusion of bivalirudin after elective percutaneous coronary intervention protects against procedural myocardial injury (a COBER study)—a randomized trial
Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after e...
Saved in:
| Published in | Scientific reports Vol. 13; no. 1; pp. 6667 - 9 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
24.04.2023
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2045-2322 2045-2322 |
| DOI | 10.1038/s41598-023-34008-y |
Cover
Loading…
| Abstract | Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included (
n
= 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%],
P
= 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%],
P
= 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) (
P
= 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%],
P
= 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding.
ClinicalTrials.gov.Number: NCT04120961, 09/10/2019. |
|---|---|
| AbstractList | Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included (
n
= 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%],
P
= 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%],
P
= 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) (
P
= 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%],
P
= 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding.
ClinicalTrials.gov.Number: NCT04120961, 09/10/2019. Abstract Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included (n = 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%], P = 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%], P = 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) (P = 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%], P = 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding. ClinicalTrials.gov.Number: NCT04120961, 09/10/2019. Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included (n = 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%], P = 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%], P = 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) (P = 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%], P = 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding.ClinicalTrials.gov.Number: NCT04120961, 09/10/2019. Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included (n = 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%], P = 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%], P = 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) (P = 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%], P = 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding.ClinicalTrials.gov.Number: NCT04120961, 09/10/2019.Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included (n = 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%], P = 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%], P = 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) (P = 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%], P = 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding.ClinicalTrials.gov.Number: NCT04120961, 09/10/2019. Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future adverse cardiac events. In this randomized pilot trial, we assessed the effects of prolonged use of the anti-coagulant bivalirudin on PMI after ePCI. Patients undergoing ePCI were randomized into the following two groups: the bivalirudin use during operation group (BUDO, 0.75 mg/kg bolus plus 1.75 mg/kg/h) and the bivalirudin use during and after operation for 4 h (BUDAO, 0.75 mg/kg bolus plus 1.75 mg/kg/h). Blood samples were collected before and 24 h after ePCI (per 8 h). The primary outcome, PMI, was defined as an increase in post-ePCI cardiac troponin I (cTnI) levels of > 1 × 99th% upper reference limit (URL) when the pre-PCI cTnI was normal or a rise in cTnI of > 20% of the baseline value when it was above the 99th percentile URL, but it was stable or falling. Major PMI (MPMI) was defined as a post-ePCI cTnI increase of > 5 × 99th% URL. A total of 330 patients were included (n = 165 per group). The incidences of PMI and MPMI were not significantly higher in the BUDO group than in the BUDAO group (PMI: 115 [69.70%] vs. 102 [61.82%], P = 0.164; MPMI: 81 [49.09%] vs. 70 [42.42%], P = 0.269). However, the absolute change in cTnI levels (calculated as the peak value 24 h post-PCI minus the pre-PCI value) was notably larger in the BUDO group (0.13 [0.03, 1.95]) than in the BUDAO group (0.07 [0.01, 0.61]) (P = 0.045). Moreover, the incidence of bleeding events was similar between the two groups (BUDO: 0 [0.00%]; BUDAO: 2 [1.21%], P = 0.498). Prolonged infusion of bivalirudin for 4 h after ePCI reduces PMI severity without increasing the risk of bleeding.ClinicalTrials.gov.Number: NCT04120961, 09/10/2019. |
| ArticleNumber | 6667 |
| Author | Guo, Yajie Wu, Xiangqi Meng, Peina Wu, Zhiming Ye, Fei You, Wei |
| Author_xml | – sequence: 1 givenname: Zhiming surname: Wu fullname: Wu, Zhiming organization: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University – sequence: 2 givenname: Peina surname: Meng fullname: Meng, Peina organization: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University – sequence: 3 givenname: Yajie surname: Guo fullname: Guo, Yajie organization: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University – sequence: 4 givenname: Wei surname: You fullname: You, Wei email: zoolandyw@163.com organization: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University – sequence: 5 givenname: Xiangqi surname: Wu fullname: Wu, Xiangqi email: wuxq2018@tom.com organization: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University – sequence: 6 givenname: Fei surname: Ye fullname: Ye, Fei email: doctor_ye@126.com organization: Department of Cardiology, Nanjing First Hospital, Nanjing Medical University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37095298$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks9u1DAQxiNUREvpC3BAlriUQ8D_knVOqFQFKlUqQnC2Jo6zeJW1F9tZaTnxEDwDD8aTMGlKaXtoLpk4v-_LzOR7Wuz54G1RPGf0NaNCvUmSVY0qKRelkJSqcveoOOBUViUXnO_dqveLo5RWFK-KN5I1T4p9saANPqiD4venGIbgl7YjzvdjcsGT0JPWbWFwceycJ9BnG4kdrMlua8nGRjNm8DaMiZgQg4e4QzFCW-vzZLCJISOdCCzB-ZSnA2O7McJA1rtgIHYOS-dXI0qPgZxevjv7TFIeu92rPz9_AYngu7B2P7CtHJF9VjzuYUj26Pp-WHx9f_bl9GN5cfnh_PTkojSVZLmse6WgB8YMa6Xi0C-4gFYo1TWqwsJK0S2ayiw4GFnVtu5r4KqxUrawaBsuDovz2bcLsNKb6NY4nA7g9NVBiEsNMTszWG3BUF6JWgjaS9uAMpZCZXsuBSigk9fb2WsztmvbGVwOLuCO6d033n3Ty7DVjDJeM1qjw_G1QwzfR5uyXrtk7DDM29dc0ZouGG0aRF_eQ1dhjB53NVH4rysuKVIvbrd008u_PCDAZ8DEkFK0_Q3CqJ5yp-fcaZxPX-VO71Ck7omMyzAlAcdyw8NSMUsTfgdTGP-3_YDqL7YX8qs |
| CitedBy_id | crossref_primary_10_1016_j_dsx_2023_102858 crossref_primary_10_1016_j_ijbiomac_2025_141950 crossref_primary_10_1186_s12872_024_04399_5 |
| Cites_doi | 10.1056/NEJMoa1507854 10.1093/eurheartj/ehq008 10.1093/eurheartj/ehab702 10.1161/CIRCRESAHA.110.235713 10.1056/NEJMoa0708191 10.14814/phy2.12874 10.1007/s00395-012-0303-3 10.1016/j.jacc.2018.12.023 10.1172/JCI116031 10.1016/j.ijcard.2015.05.188 10.1016/j.yjmcc.2011.06.022 10.1016/j.jcin.2019.07.014 10.1016/j.jcin.2021.05.006 10.1161/01.CIR.103.19.2339 10.1093/eurheartj/ehq393 10.1093/eurheartj/ehx799 10.1016/j.jcin.2008.01.005 10.1111/j.1527-3466.2005.tb00177.x 10.1007/s40119-020-00197-0 10.1016/j.amjcard.2009.06.035 10.1016/S0039-6109(16)43636-4 10.1007/s12265-021-10122-y 10.1080/14017430601071849 10.1161/CIRCINTERVENTIONS.120.009992 10.1177/0897190012442721 10.1038/s41569-021-00632-2 10.1161/CIRCULATIONAHA.109.888784 10.1152/ajpheart.01116.2006 10.2147/vhrm.2006.2.4.357 10.3760/cma.j.issn.0366-6999.20122569 10.1016/j.amjmed.2018.06.016 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-023-34008-y |
| DatabaseName | SpringerOpen CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Science Database (ProQuest) Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_eac02536330f4e9a8ce0a5ef243a8a02 PMC10126106 37095298 10_1038_s41598_023_34008_y |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Cardiocare Sponsored (CS) Optimized Antithrombotic Research Fund grantid: BJUHFCSOARF201801-13 – fundername: ; grantid: BJUHFCSOARF201801-13 |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM PJZUB PPXIY PQGLB 7XB 8FK AARCD K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c541t-6f88afa11c1b482af723ab388d985ab3e43d795c72ac456e6f6a289e44ba7b923 |
| IEDL.DBID | M48 |
| ISSN | 2045-2322 |
| IngestDate | Wed Aug 27 01:30:55 EDT 2025 Thu Aug 21 18:38:05 EDT 2025 Fri Jul 11 06:58:11 EDT 2025 Wed Aug 13 09:16:55 EDT 2025 Mon Jul 21 06:05:17 EDT 2025 Tue Jul 01 04:24:33 EDT 2025 Thu Apr 24 23:07:24 EDT 2025 Fri Feb 21 02:37:21 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c541t-6f88afa11c1b482af723ab388d985ab3e43d795c72ac456e6f6a289e44ba7b923 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Undefined-1 content type line 23 |
| OpenAccessLink | https://doaj.org/article/eac02536330f4e9a8ce0a5ef243a8a02 |
| PMID | 37095298 |
| PQID | 2805295240 |
| PQPubID | 2041939 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_eac02536330f4e9a8ce0a5ef243a8a02 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10126106 proquest_miscellaneous_2806071099 proquest_journals_2805295240 pubmed_primary_37095298 crossref_primary_10_1038_s41598_023_34008_y crossref_citationtrail_10_1038_s41598_023_34008_y springer_journals_10_1038_s41598_023_34008_y |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-04-24 |
| PublicationDateYYYYMMDD | 2023-04-24 |
| PublicationDate_xml | – month: 04 year: 2023 text: 2023-04-24 day: 24 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2023 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Heusch (CR13) 2009; 120 Tavano (CR10) 2009; 104 Garcia-Garcia (CR5) 2019; 12 Bose (CR18) 2007; 292 Lieder, Baars, Kahlert, Kleinbongard (CR17) 2016; 4 Escaned (CR23) 2021; 42 Graeber (CR25) 1985; 65 Sandhu, Nadar (CR1) 2015; 199 Hildebrandt (CR14) 2016; 12 Babu, Walker, Yellon, Hausenloy (CR6) 2011; 32 Kleinbongard, Heusch (CR12) 2022; 19 Baars (CR33) 2012; 107 Valgimigli (CR9) 2015; 373 CR4 Herrmann (CR32) 2001; 103 Schulz (CR19) 2010; 31 Lehman, Chew (CR7) 2006; 2 Stone (CR8) 2008; 358 Majithia, Bhatt (CR21) 2017; 6 Shammas (CR31) 2005; 23 Paolucci (CR2) 2021; 14 Sheikh-Taha, Ghosn (CR28) 2012; 25 Gargiulo (CR24) 2019; 73 Zeitouni (CR3) 2018; 39 Sharma, Kumar, Prashanth, Belagali (CR20) 2020; 9 Xiang (CR11) 2013; 126 Kleinbongard (CR16) 2012; 52 Kleinbongard (CR15) 2011; 108 Nelken (CR30) 1992; 90 Hedstrom (CR27) 2007; 41 Kereiakes, Gurbel (CR29) 2008; 1 Cole (CR22) 2021; 14 Wang (CR26) 2021; 14 DJ Kereiakes (34008_CR29) 2008; 1 G Gargiulo (34008_CR24) 2019; 73 J Herrmann (34008_CR32) 2001; 103 DC Xiang (34008_CR11) 2013; 126 J Cole (34008_CR22) 2021; 14 M Zeitouni (34008_CR3) 2018; 39 HM Garcia-Garcia (34008_CR5) 2019; 12 T Baars (34008_CR33) 2012; 107 E Hedstrom (34008_CR27) 2007; 41 HY Wang (34008_CR26) 2021; 14 M Sheikh-Taha (34008_CR28) 2012; 25 NA Nelken (34008_CR30) 1992; 90 L Paolucci (34008_CR2) 2021; 14 HA Hildebrandt (34008_CR14) 2016; 12 SJ Lehman (34008_CR7) 2006; 2 G Heusch (34008_CR13) 2009; 120 D Bose (34008_CR18) 2007; 292 D Tavano (34008_CR10) 2009; 104 P Kleinbongard (34008_CR15) 2011; 108 P Kleinbongard (34008_CR12) 2022; 19 34008_CR4 M Valgimigli (34008_CR9) 2015; 373 GG Babu (34008_CR6) 2011; 32 A Majithia (34008_CR21) 2017; 6 K Sandhu (34008_CR1) 2015; 199 S Schulz (34008_CR19) 2010; 31 HR Lieder (34008_CR17) 2016; 4 GW Stone (34008_CR8) 2008; 358 J Escaned (34008_CR23) 2021; 42 GM Graeber (34008_CR25) 1985; 65 NW Shammas (34008_CR31) 2005; 23 P Kleinbongard (34008_CR16) 2012; 52 R Sharma (34008_CR20) 2020; 9 |
| References_xml | – volume: 373 start-page: 997 year: 2015 end-page: 1009 ident: CR9 article-title: Bivalirudin or unfractionated heparin in acute coronary syndromes publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507854 – volume: 31 start-page: 582 year: 2010 end-page: 587 ident: CR19 article-title: Bivalirudin versus unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-Year results of the isar-react 3 trial publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehq008 – volume: 42 start-page: 4624 year: 2021 end-page: 4634 ident: CR23 article-title: Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: Twilight-hbr publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehab702 – volume: 108 start-page: 344 year: 2011 end-page: 352 ident: CR15 article-title: Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.110.235713 – ident: CR4 – volume: 358 start-page: 2218 year: 2008 end-page: 2230 ident: CR8 article-title: Bivalirudin during primary pci in acute myocardial infarction publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0708191 – volume: 126 start-page: 3064 year: 2013 end-page: 3068 ident: CR11 article-title: Evaluation on the efficacy and safety of domestic bivalirudin during percutaneous coronary intervention publication-title: Chin Med. J. (Engl). – volume: 4 start-page: e12874 year: 2016 ident: CR17 article-title: Aspirate from human stented saphenous vein grafts induces epicardial coronary vasoconstriction and impairs perfusion and left ventricular function in rat bioassay hearts with pharmacologically induced endothelial dysfunction publication-title: Physiol. Rep. doi: 10.14814/phy2.12874 – volume: 107 start-page: 303 year: 2012 ident: CR33 article-title: Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: More plaque calcification and necrosis, but less vasoconstrictor potential publication-title: Basic Res. Cardiol. doi: 10.1007/s00395-012-0303-3 – volume: 73 start-page: 758 year: 2019 end-page: 774 ident: CR24 article-title: Post-procedural bivalirudin infusion at full or low regimen in patients with acute coronary syndrome publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2018.12.023 – volume: 90 start-page: 1614 year: 1992 end-page: 1621 ident: CR30 article-title: Thrombin receptor expression in normal and atherosclerotic human arteries publication-title: J. Clin. Investig. doi: 10.1172/JCI116031 – volume: 12 start-page: 1481 year: 2016 end-page: 1489 ident: CR14 article-title: Quantification and characterisation of released plaque material during bioresorbable vascular scaffold implantation into right coronary artery lesions by multimodality intracoronary imaging publication-title: EuroIntervention J. EuroPCR Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. – volume: 199 start-page: 342 year: 2015 end-page: 355 ident: CR1 article-title: Percutaneous coronary intervention in the elderly publication-title: Int. J. Cardiol. doi: 10.1016/j.ijcard.2015.05.188 – volume: 52 start-page: 890 year: 2012 end-page: 896 ident: CR16 article-title: Lessons from human coronary aspirate publication-title: J. Mol. Cell. Cardiol. doi: 10.1016/j.yjmcc.2011.06.022 – volume: 12 start-page: 1954 year: 2019 end-page: 1962 ident: CR5 article-title: Impact of periprocedural myocardial biomarker elevation on mortality following elective percutaneous coronary intervention publication-title: JACC Cardiovasc. Interv. doi: 10.1016/j.jcin.2019.07.014 – volume: 14 start-page: 1623 year: 2021 end-page: 1634 ident: CR26 article-title: Implications of periprocedural myocardial biomarker elevations and commonly used Mi definitions after left main pci publication-title: JACC Cardiovasc. Interv. doi: 10.1016/j.jcin.2021.05.006 – volume: 103 start-page: 2339 year: 2001 end-page: 2345 ident: CR32 article-title: Abnormal coronary flow velocity reserve after coronary intervention is associated with cardiac marker elevation publication-title: Circulation doi: 10.1161/01.CIR.103.19.2339 – volume: 32 start-page: 23 year: 2011 end-page: 31 ident: CR6 article-title: Peri-procedural myocardial injury during percutaneous coronary intervention: An important target for cardioprotection publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehq393 – volume: 39 start-page: 1100 year: 2018 end-page: 1109 ident: CR3 article-title: Montalescot and action study group periprocedural myocardial infarction and injury in elective coronary stenting publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehx799 – volume: 1 start-page: 111 year: 2008 end-page: 121 ident: CR29 article-title: Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention publication-title: JACC Cardiovasc. Interv. doi: 10.1016/j.jcin.2008.01.005 – volume: 23 start-page: 345 year: 2005 end-page: 360 ident: CR31 article-title: Bivalirudin: Pharmacology and clinical applications publication-title: Cardiovasc. Drug Rev. doi: 10.1111/j.1527-3466.2005.tb00177.x – volume: 9 start-page: 349 year: 2020 end-page: 361 ident: CR20 article-title: Dual antiplatelet therapy in coronary artery disease publication-title: Cardiol. Ther. doi: 10.1007/s40119-020-00197-0 – volume: 104 start-page: 1222 year: 2009 end-page: 1228 ident: CR10 article-title: Comparison of bivalirudin monotherapy versus unfractionated heparin plus tirofiban in patients with diabetes mellitus undergoing elective percutaneous coronary intervention publication-title: Am. J. Cardiol. doi: 10.1016/j.amjcard.2009.06.035 – volume: 65 start-page: 539 year: 1985 end-page: 551 ident: CR25 article-title: Creatine kinase (Ck): Its use in the evaluation of perioperative myocardial infarction publication-title: Surg. Clin. N. Am. doi: 10.1016/S0039-6109(16)43636-4 – volume: 14 start-page: 1125 year: 2021 end-page: 1130 ident: CR2 article-title: Prediction of 5-year mortality in patients with chronic coronary syndrome treated with elective percutaneous coronary intervention: Role of the acef score publication-title: J. Cardiovasc. Transl. Res. doi: 10.1007/s12265-021-10122-y – volume: 41 start-page: 44 year: 2007 end-page: 50 ident: CR27 article-title: Peak Ckmb and Ctnt accurately estimates myocardial infarct size after reperfusion publication-title: Scand. Cardiovasc. J. doi: 10.1080/14017430601071849 – volume: 14 start-page: e009992 year: 2021 ident: CR22 article-title: Colchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention: The cope-pci pilot trial publication-title: Circ. Cardiovasc. Interv. doi: 10.1161/CIRCINTERVENTIONS.120.009992 – volume: 25 start-page: 537 year: 2012 end-page: 540 ident: CR28 article-title: Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: A retrospective observational study publication-title: J. Pharm. Pract. doi: 10.1177/0897190012442721 – volume: 19 start-page: 265 year: 2022 end-page: 280 ident: CR12 article-title: A fresh look at coronary microembolization publication-title: Nat. Rev. Cardiol. doi: 10.1038/s41569-021-00632-2 – volume: 6 start-page: 25 year: 2017 end-page: 37 ident: CR21 article-title: Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention publication-title: Interv. Cardiol. Clin. – volume: 120 start-page: 1822 year: 2009 end-page: 1836 ident: CR13 article-title: Coronary microembolization: From bedside to bench and back to bedside publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.109.888784 – volume: 292 start-page: H2295 year: 2007 end-page: 2299 ident: CR18 article-title: Release of TNF-alpha during stent implantation into saphenous vein aortocoronary bypass grafts and its relation to plaque extrusion and restenosis publication-title: Am. J. Physiol. Heart Circ. Physiol. doi: 10.1152/ajpheart.01116.2006 – volume: 2 start-page: 357 year: 2006 end-page: 363 ident: CR7 article-title: Bivalirudin in percutaneous coronary intervention publication-title: Vasc. Health Risk Manag. doi: 10.2147/vhrm.2006.2.4.357 – volume: 2 start-page: 357 year: 2006 ident: 34008_CR7 publication-title: Vasc. Health Risk Manag. doi: 10.2147/vhrm.2006.2.4.357 – volume: 12 start-page: 1481 year: 2016 ident: 34008_CR14 publication-title: EuroIntervention J. EuroPCR Collab. Work. Group Interv. Cardiol. Eur. Soc. Cardiol. – volume: 107 start-page: 303 year: 2012 ident: 34008_CR33 publication-title: Basic Res. Cardiol. doi: 10.1007/s00395-012-0303-3 – volume: 6 start-page: 25 year: 2017 ident: 34008_CR21 publication-title: Interv. Cardiol. Clin. – volume: 65 start-page: 539 year: 1985 ident: 34008_CR25 publication-title: Surg. Clin. N. Am. doi: 10.1016/S0039-6109(16)43636-4 – volume: 73 start-page: 758 year: 2019 ident: 34008_CR24 publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2018.12.023 – volume: 42 start-page: 4624 year: 2021 ident: 34008_CR23 publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehab702 – volume: 23 start-page: 345 year: 2005 ident: 34008_CR31 publication-title: Cardiovasc. Drug Rev. doi: 10.1111/j.1527-3466.2005.tb00177.x – volume: 41 start-page: 44 year: 2007 ident: 34008_CR27 publication-title: Scand. Cardiovasc. J. doi: 10.1080/14017430601071849 – volume: 292 start-page: H2295 year: 2007 ident: 34008_CR18 publication-title: Am. J. Physiol. Heart Circ. Physiol. doi: 10.1152/ajpheart.01116.2006 – volume: 19 start-page: 265 year: 2022 ident: 34008_CR12 publication-title: Nat. Rev. Cardiol. doi: 10.1038/s41569-021-00632-2 – volume: 120 start-page: 1822 year: 2009 ident: 34008_CR13 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.109.888784 – volume: 108 start-page: 344 year: 2011 ident: 34008_CR15 publication-title: Circ. Res. doi: 10.1161/CIRCRESAHA.110.235713 – volume: 4 start-page: e12874 year: 2016 ident: 34008_CR17 publication-title: Physiol. Rep. doi: 10.14814/phy2.12874 – volume: 25 start-page: 537 year: 2012 ident: 34008_CR28 publication-title: J. Pharm. Pract. doi: 10.1177/0897190012442721 – volume: 199 start-page: 342 year: 2015 ident: 34008_CR1 publication-title: Int. J. Cardiol. doi: 10.1016/j.ijcard.2015.05.188 – volume: 373 start-page: 997 year: 2015 ident: 34008_CR9 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1507854 – volume: 126 start-page: 3064 year: 2013 ident: 34008_CR11 publication-title: Chin Med. J. (Engl). doi: 10.3760/cma.j.issn.0366-6999.20122569 – volume: 14 start-page: 1125 year: 2021 ident: 34008_CR2 publication-title: J. Cardiovasc. Transl. Res. doi: 10.1007/s12265-021-10122-y – volume: 14 start-page: e009992 year: 2021 ident: 34008_CR22 publication-title: Circ. Cardiovasc. Interv. doi: 10.1161/CIRCINTERVENTIONS.120.009992 – volume: 14 start-page: 1623 year: 2021 ident: 34008_CR26 publication-title: JACC Cardiovasc. Interv. doi: 10.1016/j.jcin.2021.05.006 – volume: 1 start-page: 111 year: 2008 ident: 34008_CR29 publication-title: JACC Cardiovasc. Interv. doi: 10.1016/j.jcin.2008.01.005 – volume: 9 start-page: 349 year: 2020 ident: 34008_CR20 publication-title: Cardiol. Ther. doi: 10.1007/s40119-020-00197-0 – volume: 32 start-page: 23 year: 2011 ident: 34008_CR6 publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehq393 – volume: 358 start-page: 2218 year: 2008 ident: 34008_CR8 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0708191 – volume: 104 start-page: 1222 year: 2009 ident: 34008_CR10 publication-title: Am. J. Cardiol. doi: 10.1016/j.amjcard.2009.06.035 – volume: 39 start-page: 1100 year: 2018 ident: 34008_CR3 publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehx799 – volume: 90 start-page: 1614 year: 1992 ident: 34008_CR30 publication-title: J. Clin. Investig. doi: 10.1172/JCI116031 – volume: 12 start-page: 1954 year: 2019 ident: 34008_CR5 publication-title: JACC Cardiovasc. Interv. doi: 10.1016/j.jcin.2019.07.014 – ident: 34008_CR4 doi: 10.1016/j.amjmed.2018.06.016 – volume: 52 start-page: 890 year: 2012 ident: 34008_CR16 publication-title: J. Mol. Cell. Cardiol. doi: 10.1016/j.yjmcc.2011.06.022 – volume: 31 start-page: 582 year: 2010 ident: 34008_CR19 publication-title: Eur. Heart J. doi: 10.1093/eurheartj/ehq008 – volume: 103 start-page: 2339 year: 2001 ident: 34008_CR32 publication-title: Circulation doi: 10.1161/01.CIR.103.19.2339 |
| SSID | ssj0000529419 |
| Score | 2.4035213 |
| Snippet | Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with future... Abstract Procedural myocardial injury (PMI), which is the most common complication of elective percutaneous coronary intervention (ePCI), is associated with... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 6667 |
| SubjectTerms | 692/4019 692/4019/2776 Angioplasty Anticoagulants Bleeding Heart Hemorrhage - etiology Hirudins Humanities and Social Sciences Humans multidisciplinary Myocardial Infarction - etiology Peptide Fragments - adverse effects Percutaneous Coronary Intervention - adverse effects Science Science (multidisciplinary) Treatment Outcome Troponin I |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLVQpUpsEJRXoCAjsQBB1MSPxFnSqlWFxEOISt1ZN44NqdqZKjNZhFU_ot_Ah_VLem1nhhmeG3ZRYkuW77m-x7n2uYQ8N8AzqIxIrTNZKgpZpTVvHLq75ZkxXLpwPfrd--LwSLw9lscrpb78mbAoDxwnbgcXBgzLvMB9txO2AmVsBtI6JjgoiDKSGPNWNlNR1ZtVIq_GWzIZVzszjFT-NhnjKRc-5z-sRaIg2P87lvnrYcmfMqYhEB3cJrdGBknfxJHfITfsZItsxpqSw13y_WOHT9ixoQie3v8Mo1NH6xYh1XY9hioa6oLTUAAH1zp6bjvTI0e0035GjVc0gG6g7cphSDqqOcwofIEWCSUNca_xkh30bMBw6GF2in1O0ET0BdC9D7v7n2jQrn15dXEJFENiMz1rv-GwQqGQe-ToYP_z3mE6FmNIjRT5PC2cUuAgz01eC8XAlYxDzZVqKiXxwQrelJU0JQODpMwWrgDczFkhaihrpJH3ycZkOrEPCS2Bg5AAhZQgyjqHBpeRxjSZCVlBl5B8YRhtRqVyXzDjVIeMOVc6GlOjMXUwph4S8mrZ5zzqdPy19a6397Kl19gOLxB5ekSe_hfyErK9QIseHX-mmQqpU-RJCXm2_Iwu6_Mw0ZK-jVf1Q26ekAcRXMuR8BI5L6tUQtQa7NaGuv5l0n4NsuBeqQ3JcJGQ1wuE_hjXn-fi0f-Yi8fkJvOulYmUiW2yMe96-wTZ2rx-GhzzGufTQUc priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3LbtQwFLWgCIkN4k2gICOxAEHUxI_EWSFataqQeAhRaXbWjWO3Qe1kSCaLsOIj-AY-jC_h2slMGR7dRYktObn3-pz42ucS8tQAT6AwIrbOJLHIZBGXvHIY7pYnxnDpwvHot--ywyPxZiZn04JbN22rXM2JYaKuGuPXyHeYCjkpBKBXiy-xrxrls6tTCY3L5IqXLvM_X_ksX6-x-B4iLaazMglXOx3ilT9TxnjMhc_8Dxt4FGT7_8U1_94y-UfeNMDRwQ1yfeKR9PVo-Jvkkp3fIlfHypLDbfLjQ4tX2LGi6EK9XxKjjaNljY5Vtz0CFg3VwWkog4MzHl3Y1vTIFG3Td9R4XQNoB1r_tiWSTpoOHYVjqJFW0oB-lRfuoGcDgqJ3tlPs8xkNRZ8B3Xu_u_-RBgXb5z-_fQeKwFg1Z_VXHFYoF3KHHB3sf9o7jKeSDLGRIl3GmVMKHKSpSUuhGLiccSi5UlWhJF5Ywau8kCZnYJCa2cxlgL90VogS8hLJ5F2yNW_m9j6hOXAQEiCTEkReplDhZFKZKjEhN-gikq4Mo82kV-7LZpzqkDfnSo_G1GhMHYyph4i8WPdZjGodF7be9fZet_RK2-FG0x7rKXA1AhPSQp5xnjhhC1DGJiCtY4KDgoRFZHvlLXoK_06fO2tEnqwfY-D6bMxoSd_Ga_shQ4_IvdG51iPhOTJfVqiIqA232xjq5pN5fRLEwb1eG1LiLCIvVx56Pq7_f4sHF7_GQ3KN-aBJRMzENtlatr19hGxsWT4OIfcLlME4bw priority: 102 providerName: ProQuest – databaseName: SpringerOpen dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3NbtQwEB6VIiQuiH8CBRmJAwgiEttJnCNdtaqQ-BGiUm_WxLHboHa3yu4ewomH4Bl4MJ6EsfMDCwWJmxXb0igz4_mSGX8D8MSgSLA0MrbOJLHMszKuRO3I3a1IjBGZC9ej37zNDw7l66PsaAv4eBcmFO0HSstwTI_VYS-XFGj8ZTAuYiF9yr67BJc9dbsv45vls-m_is9cybQc7sckQl2wdSMGBar-i_Dln2WSv-VKQwjavw7XBuzIXvXS3oAtO78JV_pukt0t-Pa-pRFtrBmZzdr_BmMLx6qGjKlp1xSkWOgIzkLrGzrl2LltzZrQoaXPf2Y8lwG2HWt-KYNkA4_DkuExNgQlWYh4tSfrYGcdBUJvYKe05xMphz1FNnu3u_eBBdbaZ9-_fEVGwbBenDWfSazQIuQ2HO7vfZwdxEMbhthkMl3FuVMKHaapSSupOLqCC6yEUnWpMhpYKeqizEzB0RAcs7nLkT7jrJQVFhUByDuwPV_M7T1gBQqUGWKeZSiLKsWaDpDa1IkJ-UAXQToqRpuBo9y3yjjVIVculO6VqUmZOihTdxE8n_ac9wwd_1y96_U9rfTs2uHBoj3Wg7VpCkYEBUUuROKkLVEZm2BmHZcCFSY8gp3RWvTg8kvNVUiaEkKK4PE0Tc7qMzC9Jv0az-dHqDyCu71xTZKIgtAuL1UEasPsNkTdnJk3J4EQ3HO0EQzOI3gxWuhPuf7-Lu7_3_IHcJV7J0pkzOUObK_atX1IiGxVPQou-AP9zDbJ priority: 102 providerName: Springer Nature |
| Title | Prolonged infusion of bivalirudin after elective percutaneous coronary intervention protects against procedural myocardial injury (a COBER study)—a randomized trial |
| URI | https://link.springer.com/article/10.1038/s41598-023-34008-y https://www.ncbi.nlm.nih.gov/pubmed/37095298 https://www.proquest.com/docview/2805295240 https://www.proquest.com/docview/2806071099 https://pubmed.ncbi.nlm.nih.gov/PMC10126106 https://doaj.org/article/eac02536330f4e9a8ce0a5ef243a8a02 |
| Volume | 13 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fj5NAEJ7cj2juxfhb9GzWxAeNcgK7wPJgTNv0cmly5-W0Sd_IsCwnpteetE3Ev8c_1NmFVqs9nyCwmwzMDPPBsN8H8FIh9zBRwtWF8lwRhYmb8bygdNfcU4qHhV0efXoWnYzEcByOd2Ald9TewPnWVzujJzWqJkffv9UfKOHfN0vG5bs5FSGzUCzgLhemnV_vwj5VpthIOZy2cL_h-g4S4Sft2pntUw_gNo8JdwSJ3ChVltF_Gwz992_Kv1qqtlId34U7LcRk3SYm7sGOnt6HW43oZP0Afp5XtEcTc0bXuzRfy9isYFlJMVdWS6plzAqHM6uQQw9Ddq0rtSQQqWfLOVOG8gCrmpV__C3JWrqHOcNLLAlxMlsYc8Ppwa5qqpcmDic05yv5kL1C1v_YG1wwS2772kVGFTOfXZU_yCirI_IQRseDz_0Tt9VqcFUo_IUbFVJigb6v_EzIAIs44JhxKfNEhrSjBc_jJFRxgIowm46KCOldTwuRYZwRynwEe9PZVD8BFiNHESJGYYgiznzM6SmTq9xTtmlYOOCv3JKqlsjc6GlMUttQ5zJtvJqSV1Pr1bR24M16znVD4_Hf0T3j7fVIQ8FtD8yqy7TN6JQqFuFFHnHuFUInKJX2MNRFIDhK9AIHDlexkq7COg2k7awSjHLgxfo0ZbRp0zR-NGMM6R9BdwceN6G1tmQVmg7IjaDbMHXzzLT8YlnDDZEbYeXIgber-Pxt18334umNNjyDg8AkjifcQBzC3qJa6ueE0BZZB3bjcdyB_W53-GlI297g7PyCjvajfsd-9ejYxPwF4y0_5A |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELaqVgguiH8CBYwEEgiiJraTOAeE2LLVlrZLVbVSb-nEcUpQu1myu0LhxEPwDBx5KJ6EsZNsWX566y3a2NJs5psfe-xvCHmigHsQK-HqXHmuCIPYTXmWo7lr7inFg9xej94ZhoMD8e4wOFwiP7q7MOZYZecTraPOSmX2yNeYtDUpDECvx59c0zXKVFe7FhoNLLZ0_RmXbJNXm29Rv08Z2-jvrw_ctquAqwLhT90wlxJy8H3lp0IyyCPGIeVSZrEM8EELnkVxoCIGCrMLHeYh4KpEC5FClMaG6ABd_orgmCosk5Vef7i7N9_VMTIKP25v53hcrk0wQppbbIy7XJizBvVCBLSNAv6V3f59SPOPSq0NgBvXyNU2c6VvGqhdJ0t6dINcanpZ1jfJ990Kn3BiRhG0M7MJR8ucpgVCuahmGCKp7UdObeMd9LF0rCs1w9xUl7MJVYZJAaqaFr8dwqQti8SEwjEUmMhSG28zQxVCT2sMwwbeJzjnI0KDPgO6_r7X36OWM_f5z6_fgGIozsrT4guKZRuU3CIHF6Ku22R5VI70XUIj4CACgDAIQESpDxm6r0xlnrLVyNwhfqeYRLUM6aZRx0liK_VcJo0yE1RmYpWZ1A55MZ8zbvhBzh3dM_qejzTc3vaHsjpOWleRYCjERJSHnHu50DFIpT0IdM4EBwkec8hqh5akdTiT5Mw8HPJ4_hpdhan_NJo0YwybIK4JHHKnAddcEh5hrs1i6RC5ALsFURffjIoPlo7cMMRhEh465GWH0DO5_v8t7p3_Nx6Ry4P9ne1ke3O4dZ9cYcaAPOEysUqWp9VMP8BccJo-bA2QkqOLtvlfPWZ28g |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtQwELWqIhAviDuBAkYCCQTRJraTOA8I0ZtaCqVCVNq3dOLYJajdLNldofDER_ANfASfw5cwdpIty6VvfYs2tuTNnLnYMz5DyEMFPIBUCV8bFfgijlI_54VBddc8UIpHxl2PfrMbb-2LV8NouER-9HdhbFllbxOdoS4qZc_IB0y6nBQ6oIHpyiL21jdfjD_5toOUzbT27TRaiOzo5jNu3ybPt9dR1o8Y29x4v7bldx0GfBWJcOrHRkowEIYqzIVkYBLGIedSFqmM8EELXiRppBIGCiMNHZsYcIeihcghyVNLeoDm_1zC0W2iLiXDZH6-Y1crwrS7pxNwOZigr7T32Rj3ubBVB82CL3QtA_4V5_5drvlHzta5ws3L5FIXw9KXLeiukCU9ukrOt10tm2vk-16NTzixoAjfmT2Oo5WheYmgLusZOkvqOpNT14IHrS0d61rNMErV1WxCleVUgLqh5W_lmLTjk5hQOIQSQ1rqPG9hSUPocYMO2QL9COd8RJDQx0DX3q5uvKOOPffJz6_fgKJTLqrj8gsuy7UquU72z0RYN8jyqBrpW4QmwEFEAHEUgUjyEAo0ZIUqAuXyksYjYS-YTHVc6bZlx1HmcvZcZq0wMxRm5oSZNR55Op8zbplCTh29auU9H2lZvt0PVX2YdUYjQ6eIISmPOQ-M0ClIpQOItGGCg4SAeWSlR0vWmZ5JdqIoHnkwf41Gw2aCWknaMZZXEHcHHrnZgmu-Ep5g1M1S6RG5ALuFpS6-GZUfHDG55YrDcDz2yLMeoSfr-v-3uH3637hPLqCmZ6-3d3fukIvM6k8gfCZWyPK0num7GBRO83tO-yg5OGt1_wU4m3nC |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prolonged+infusion+of+bivalirudin+after+elective+percutaneous+coronary+intervention+protects+against+procedural+myocardial+injury+%28a+COBER+study%29-a+randomized+trial&rft.jtitle=Scientific+reports&rft.au=Wu%2C+Zhiming&rft.au=Meng%2C+Peina&rft.au=Guo%2C+Yajie&rft.au=You%2C+Wei&rft.date=2023-04-24&rft.eissn=2045-2322&rft.volume=13&rft.issue=1&rft.spage=6667&rft_id=info:doi/10.1038%2Fs41598-023-34008-y&rft_id=info%3Apmid%2F37095298&rft.externalDocID=37095298 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |